c-Met, DFNB97, AUTS9, c met, D249, Hepatocyte growth factor receptor, HGF, HGF receptor, HGF/SF receptor, HGFR, MET, Met proto oncogene tyrosine kinase, MET proto oncogene, receptor tyrosine kinase, Met proto-oncogene (hepatocyte growth factor receptor), Met proto-oncogene, Met protooncogene, MET_HUMAN, Oncogene MET, Par4, Proto-oncogene c-Met, RCCP2, Scatter factor receptor, SF receptor, Tyrosine-protein kinase Meta
MET (cMET) is a receptor-like tyrosine kinase whose dysregulation has been linked to many types of human malignancies. After activation of the ligand, MET interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, and STAT3. There interactions lead to the activation of signaling cascades including RAS-ERK, PI3, kinase-AKT, and PLCgamma-PKC. MET plays a role in embryonic development including gastrulation, development of muscles and neurons, angiogenesis, and kidney formation. It also plays a role in adults including wound healing, organ regeneration, and tissue remodeling. MET has been linked to cancers including gastric, renal, and breast, therefore, making it a target for cancer therapeutics and diagnostic testing.
Samples:
FFPE tissue
Target:
Human c-Met
IHC0589H
* VAT and and shipping costs not included. Errors and price changes excepted
